Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budoprutug in Immune Thrombocytopenia (ITP)
NCT07043946Phase 2Recruiting
- Sponsor
- Climb Bio
- Start
- Jun 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, open-label trial of budoprutug in immune thrombocytopenia (ITP) (4 cohorts), sponsored by Climb Bio. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 48 weeks. Started Jun 2025; status: recruiting.
02
Drugs
budoprutug
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07043946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07043946.